Andrew Goldsborough | CEO
RNAssist

Andrew Goldsborough is an accomplished inventor and founder of RNAssist with over 25 years of experience in the development of stabilization technologies for the life sciences. He has successfully founded and led three biotechnology companies, each specializing in advanced solutions for stabilizing RNA, DNA, proteins, and vaccines, his work has resulted in multiple broad patents and licensed products.

Prior to RNAssist, Andrew spent five years at the University of California, San Francisco (UCSF), where he gained significant expertise in biochemistry and molecular biology. His extensive research background paved the way for the creation of several groundbreaking reagents, including TheraPHIX™, vivoPHIX™, genoPHIX™ and virusPHIX™ which tackle key challenges in ambient liquid-stable mRNA transport, tissue and cell fixation, and virus inactivation. Notably, TheraPHIX™ provides a transformative solution for ambient liquid-stable mRNA therapeutics and vaccine transport, eliminating cold chain dependency and improving global accessibility to these critical therapies.